000			02358 a2200685 4500
005			20250517111923.0
264		0	_c20180223
008			201802s 0 0 eng d
022			_a1949-2553
024	7		_a10.18632/oncotarget.11100 _2doi
040			_aNLM _beng _cNLM
100	1		_aBocchia, Monica
245	0	0	_aGenetic predisposition and induced pro-inflammatory/pro-oxidative status may play a role in increased atherothrombotic events in nilotinib treated chronic myeloid leukemia patients. _h[electronic resource]
260			_bOncotarget _cNov 2016
300			_a72311-72321 p. _bdigital
500			_aPublication Type: Comparative Study; Journal Article
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aAntineoplastic Agents _xtherapeutic use
650	0	4	_aAtherosclerosis _xblood
650	0	4	_aCross-Sectional Studies
650	0	4	_aCytokines _xblood
650	0	4	_aDyslipidemias _xblood
650	0	4	_aFemale
650	0	4	_aGenetic Predisposition to Disease
650	0	4	_aHumans
650	0	4	_aImatinib Mesylate _xtherapeutic use
650	0	4	_aIncidence
650	0	4	_aInflammation _xchemically induced
650	0	4	_aLeukemia, Myelogenous, Chronic, BCR-ABL Positive _xdrug therapy
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aOxidation-Reduction _xdrug effects
650	0	4	_aPolymorphism, Single Nucleotide
650	0	4	_aProspective Studies
650	0	4	_aProtein Kinase Inhibitors _xtherapeutic use
650	0	4	_aPyrimidines _xtherapeutic use
650	0	4	_aRetrospective Studies
650	0	4	_aRisk Factors
650	0	4	_aScavenger Receptors, Class E _xgenetics
650	0	4	_aThrombosis _xblood
700	1		_aGalimberti, Sara
700	1		_aAprile, Lara
700	1		_aSicuranza, Anna
700	1		_aGozzini, Antonella
700	1		_aSantilli, Francesca
700	1		_aAbruzzese, Elisabetta
700	1		_aBaratè, Claudia
700	1		_aScappini, Barbara
700	1		_aFontanelli, Giulia
700	1		_aTrawinska, Monika Malgorzata
700	1		_aDefina, Marzia
700	1		_aGozzetti, Alessandro
700	1		_aBosi, Alberto
700	1		_aPetrini, Mario
700	1		_aPuccetti, Luca
773	0		_tOncotarget _gvol. 7 _gno. 44 _gp. 72311-72321
856	4	0	_uhttps://doi.org/10.18632/oncotarget.11100 _zAvailable from publisher's website
999			_c26331171 _d26331171